Charles River Laboratories International, Inc. $CRL Shares Sold by Investment House LLC

Investment House LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 52.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,413 shares of the medical research company’s stock after selling 34,167 shares during the period. Investment House LLC owned approximately 0.06% of Charles River Laboratories International worth $4,766,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Exchange Traded Concepts LLC increased its holdings in Charles River Laboratories International by 1.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock valued at $871,000 after purchasing an additional 76 shares during the last quarter. Brooklyn Investment Group raised its holdings in shares of Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after buying an additional 86 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Charles River Laboratories International by 1.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after acquiring an additional 86 shares in the last quarter. WESCAP Management Group Inc. boosted its holdings in Charles River Laboratories International by 3.8% during the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after acquiring an additional 89 shares during the period. Finally, State of New Jersey Common Pension Fund D grew its position in Charles River Laboratories International by 0.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 109 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on CRL shares. Argus set a $200.00 price objective on shares of Charles River Laboratories International in a research note on Monday, November 17th. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, October 3rd. TD Cowen cut their price target on Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Finally, Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $190.86.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $194.65 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The firm has a market cap of $9.58 billion, a PE ratio of -124.78, a price-to-earnings-growth ratio of 6.57 and a beta of 1.63. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $200.10. The company’s 50 day simple moving average is $176.72 and its 200-day simple moving average is $162.69.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.59 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).